Related Experiment Video
Updated: Feb 16, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Recent advances in the treatment of skin involvement in systemic sclerosis
1Department of Dermatology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655 Japan.
Abstract:
Skin fibrosis is a devastating clinical condition commonly seen in skin-restricted and systemic disorders. The goal of skin fibrosis treatment is the restoration of abnormally activated dermal fibroblasts producing the excessive amount of extracellular matrix, which is generally a final consequence of the complex disease process including the activation of vascular and immune systems. Among various skin fibrotic conditions, the molecular mechanisms underlying dermal fibroblast activation have been mostly well studied in systemic sclerosis (SSc). SSc is a multisystem autoimmune and vascular disease resulting in extensive fibrosis of the skin and various internal organs. Since SSc pathogenesis is believed to include all the critical components regulating tissue fibrosis, the studies on anti-fibrotic drugs against SSc provide us much useful information regarding the strategy for the treatment of various skin fibrotic conditions. In the recent decade, as is the case with other autoimmune and inflammatory diseases, the molecular targeting therapy with monoclonal antibody has been clinically well examined in SSc. Promising clinical outcomes are so far reported in tocilizumab (an anti-IL-6 receptor antibody), rituximab (an anti-CD20 antibody), and fresolimumab (an anti-TGF-β antibody). The analysis of gene expression profiles in skin lesions of SSc patients treated with tocilizumab or fresolimumab revealed a critical role of monocyte-macrophage lineage cells in the development of skin fibrosis and the involvement of IL-6 and TGF-β in the activation of those cells. Considering that B cells modulate the differentiation and activation of macrophages, favorable clinical outcomes of rituximab treatment imply the central role of B cell/monocyte-macrophage lineage cell axis in the pathogenesis of SSc. This scenario may be applicable at least partly to other skin fibrotic conditions. In this review article, the currently available data on these drugs are summarized and the future directions are discussed.
Insights
Targeting fibroblast activation is key for skin fibrosis treatment. Monoclonal antibodies targeting IL-6, CD20, and TGF-β show promise, highlighting the role of immune cells in fibrosis.
Area of Science:
- Immunology
- Dermatology
- Rheumatology
Background:
- Skin fibrosis, a hallmark of various disorders, involves excessive extracellular matrix production by activated dermal fibroblasts.
- Systemic sclerosis (SSc) serves as a model for studying skin fibrosis due to its complex pathogenesis involving immune and vascular systems.
- Understanding fibroblast activation mechanisms is crucial for developing effective anti-fibrotic therapies.
Purpose of the Study:
- To review current data on molecularly targeted therapies for skin fibrosis, particularly in SSc.
- To discuss the role of immune cell lineages, specifically B cells and monocyte-macrophages, in SSc pathogenesis.
- To explore future therapeutic strategies for skin fibrotic conditions.
Main Methods:
- Review of clinical trial data for monoclonal antibodies in SSc.
- Analysis of gene expression profiles in SSc skin lesions.
- Evaluation of the impact of IL-6, TGF-β, and CD20 targeting on immune cell function and fibrosis.
Main Results:
- Tocilizumab (anti-IL-6 receptor), rituximab (anti-CD20), and fresolimumab (anti-TGF-β) have shown promising clinical outcomes in SSc.
- Gene expression analysis revealed monocyte-macrophage lineage cells are critical in fibrosis development, with IL-6 and TGF-β involvement.
- Rituximab's efficacy suggests a central role for the B cell/monocyte-macrophage axis in SSc pathogenesis.
Conclusions:
- Monoclonal antibody therapies targeting specific immune pathways offer a promising avenue for treating skin fibrosis.
- The B cell/monocyte-macrophage axis is a key player in SSc and potentially other fibrotic conditions.
- Further research into these targeted therapies and their mechanisms is warranted for improved patient outcomes.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Clinical Applications of Epidermal Stem Cells
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management

